NantOmics
{{Infobox company
| name = NantOmics, LLC
| logo =
| type = Limited liability
| industry = Biotechnology, molecular diagnostics
| fate =
| predecessor =
| successor =
| founded = 2013
| founder = Patrick Soon-Shiong
| defunct =
| hq_location_city = Culver City, California
| hq_location_country = United States
| area_served =
| key_people =
| products = Molecular diagnostic products
| owner =
| num_employees =
| num_employees_year =
| parent =
| website = https://nantomics.com
}}
NantOmics is a biotechnology company based in Culver City, California, which provides molecular diagnostic products for personalized cancer treatment. It is part of the NantWorks network, a corporation consisting of different startups in the medical and health industry.{{Cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=253682506|archive-url=https://web.archive.org/web/20180331040735/https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=253682506|url-status=dead|archive-date=March 31, 2018|title=NantOmics, LLC: Private Company Information - Bloomberg|website=www.bloomberg.com|access-date=2018-03-30}}
History
NantOmics was founded in 2013 by billionaire Patrick Soon-Shiong. In 2015 NantOmics bought the cancer diagnostics company OncoPlex Dx.{{Cite news|url=https://www.businesswire.com/news/home/20150910006491/en/NantOmics-Acquires-OncoPlex-Diagnostics-Accredited-Proteomics-Diagnostic|title=NantOmics Acquires OncoPlex Diagnostics, an Accredited Proteomics Diagnostic Laboratory|access-date=2018-03-30|language=en}} In 2017 the company acquired the consumer genomics startup Genos.{{Cite web|url=http://www.bio-itworld.com/2017/04/13/nantomics-acquires-genos.aspx|title=Bio-IT World|website=www.bio-itworld.com|language=en-us|access-date=2018-03-30}} Three years later, in 2020, NantOmics shutdown Genos.{{Cite web |title=NantOmics Shuts Down Genos Direct-to-Consumer Genomics Services |url=https://www.genomeweb.com/sequencing/nantomics-shuts-down-genos-direct-consumer-genomics-services |website=genomeweb}}
Products
GPS Cancer involves sequencing of the genome and RNA of tumor cells in comparison to normal cells from the same individual in order to develop personalized treatments.{{Cite web|url=http://www.gpscancer.com/overview/|title=GPS Cancer Overview|website=GPS Cancer|language=en-US|access-date=2018-03-30}} About 327,000 cancer patients participated in a GPS cancer pilot project in 2017.{{Cite news|url=https://www.businesswire.com/news/home/20170510006569/en/NantHealth-Reports-16-Increase-2017-Quarter-Total|title=NantHealth Reports 16% Increase in 2017 First Quarter Total Net Revenue; SaaS Revenue Rose 11% and GPS Adoption Continues to Climb|access-date=2018-03-30|language=en}}